High dose-vis649    (DrugBank: -)

1 disease
告示番号疾患名(ページ内リンク)臨床試験数
66IgA腎症1

66. IgA腎症 [臨床試験数:199,薬物数:214(DrugBank:57),標的遺伝子数:32,標的パスウェイ数:128
Searched query = "IgA nephropathy", "IgA nephritis", "Berger disease", "IgA-IgG nephropathy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 199 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04287985
(ClinicalTrials.gov)
July 20, 202010/2/2020Safety and Efficacy Study of VIS649 for IgA NephropathyA Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy and Safety of VIS649 in Participants With Immunoglobulin A (IgA) NephropathyImmunoglobulin A Nephropathy;Glomerular Disease;IgANDrug: Dose-Placebo;Drug: Low Dose-VIS649;Drug: Medium Dose-VIS649;Drug: High Dose-VIS649Visterra, Inc.NULLRecruiting18 YearsN/AAll144Phase 2United States;Japan;Korea, Republic of;Spain